Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The cancer has been confirmed by laboratory testing to be HER2-positive breast cancer, meaning the HER2 protein was either strongly present on testing, or moderately present with a gene test confirming the HER2 gene is amplified.
- Before surgery, the person received a treatment plan that included at least 6 rounds of chemotherapy (with at least 4 of those rounds using a taxane-based chemotherapy drug) combined with at least 4 rounds of trastuzumab (including biosimilar or under-the-skin versions of trastuzumab).
- Surgery to remove the cancer has been completed, and testing of the removed tissue confirmed that active invasive cancer was still present in the breast and/or underarm lymph nodes after the pre-surgery treatment.
- The hormone receptor status of the cancer (such as oestrogen or progesterone receptor status) is known.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- The person has another active cancer elsewhere in the body, except for skin basal cell carcinoma or early-stage cervical cancer that has already been successfully treated.
- The breast cancer has spread to other parts of the body (stage IV metastatic breast cancer).
- The person's medical records, pathology results, or follow-up information are incomplete (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Three-year invasive disease-free survival (iDFS) rate for non-pCR patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.